Synergetics Soars 31% On FDA News (SURG, AAV, SNTA, DB, VRTX)
Synergetics USA Inc (NASDAQ:SURG) is one of the top percentage gainer and surged up 31.32% to $5.05 in the early trading hours. The Company announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for VersaVIT™, a novel vitrectomy system for the retinal surgery market.
“The entry of VersaVIT into the global vitrectomy market is a major milestone in Synergetics’ strategy to enter into higher growth areas of retinal surgery,” said David M. Hable, President and CEO. “We believe that VersaVIT is a ‘game changer’ given its functionality, portability and competitive pricing relative to traditional vitrectomy systems.” The Company is awaiting CE mark approval, which has been submitted and is currently under review.
Advantage Oil & Gas Ltd (NYSE:AAV) jumped 12.09% to $3.06 on a traded volume of 25k shares. The 52-week range for the stock is $2.47 and $8.17. The Company has Price/Sales ratio of 1.57 and Price/Book ratio of 0.41. The 50-Day Moving Average and 200-Day Moving Average prices is $2.83 and 3.42 respectively.
Synta Pharmaceuticals Corp (NASDAQ:SNTA) is one of the top losers. The stock slipped to 18.94% to $5.88 on a traded volume of 81k shares. The Company said an interim analysis of the Company’s experimental treatment for non-small cell lung cancer found improvements in progression-free survival in its co-primary patient groups. The Company didn’t present statistical analysis on the results because the data wasn’t yet mature. Synta Pharmaceuticals noted the sample size in the study’s populations is small compared to the total planned sizes.
Deutsche Bank AG (USA) (NYSE:DB) declined 4.95% to $33.57. According to report from Reuter, Deutsche Bank AG resigned as the lead underwater for iWatt Inc’s initial public offering after a dispute with the Company’s chief executive over valuation.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) among the losers in NASDAQ and the stock decreased 8.17% to $56.13. The Company announced the final data from a Phase 2 study of VX-809 and KALYDECO that showed statistically significant improvements in lung function among adults with cystic fibrosis who have two copies of the most common mutation in the cystic fibrosis transmembrane conductance regulator gene.